– Late-breaking results from global Phase 3 confirmatory studies of PADCEV (EV-302) in locally advanced or metastatic bladder cancer and TIVDAK (innovaTV 301) in recurrent or metastatic cervical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results